title: Effect of patient's life expectancy on the cost-effectiveness of treatment for ocular hypertension.
abstract: OBJECTIVE
  To assess the influence of expected life span on the cost-effectiveness of treating ocular hypertension to prevent primary open-angle glaucoma.
  
  
  METHODS
  We used a Markov simulation model to estimate the cost and benefit of ocular hypertension treatment over a person's remaining life. We examined the influence of age on the cost-effectiveness decision in 2 ways: (1) by evaluating specific age cohorts to assess the influence of age at the initiation of treatment; and (2) by evaluating the influence of a specific life span.
  
  
  RESULTS
  At a willingness to pay $50,000/quality-adjusted life year to $100,000/quality-adjusted life year, treatment of people with a 2% or greater annual risk of developing glaucoma was cost-effective for people aged 45 years with a life expectancy of at least 18 remaining years. However, to be cost-effective, a person aged 55 years must have a life expectancy of 21 remaining years and someone aged 65 years must have a life expectancy of 23 remaining years.
  
  
  CONCLUSIONS
  A person with ocular hypertension must have a life expectancy of at least 18 remaining years to justify treatment at a threshold of a 2% or greater annual risk of developing glaucoma. Persons at higher levels of risk require a life expectancy of 7 to 10 additional years to justify treatment.
authors.affiliation: Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, Campus Box 8096, 660 S Euclid Ave, St Louis, MO 63110-1093, USA. kymes@vrcc.wustl.edu
authors.forename: Steven M
authors.initials: SM
authors.lastname: Kymes
authors.forename: Michael R
authors.initials: MR
authors.lastname: Plotzke
authors.forename: Michael A
authors.initials: MA
authors.lastname: Kass
authors.forename: Michael V
authors.initials: MV
authors.lastname: Boland
authors.forename: Mae O
authors.initials: MO
authors.lastname: Gordon
mesh_terms: D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000191:economics; D003362:Cost-Benefit Analysis; D016527:Drug Costs / Q000706:statistics & numerical data; D005902:Glaucoma, Open-Angle / Q000517:prevention & control; D017048:Health Care Costs / Q000706:statistics & numerical data*; D006801:Humans; D008017:Life Expectancy; D008390:Markov Chains; D008875:Middle Aged; D015233:Models, Statistical; D009798:Ocular Hypertension / Q000188:drug therapy / Q000191:economics*; D010361:Patients; D019057:Quality-Adjusted Life Years; D012307:Risk Factors
chemical_list: D000959:Antihypertensive Agents
references.citation: Ophthalmology. 2003 Dec;110(12):2310-7
references.pmid: 14644712
references.citation: J Glaucoma. 1998 Apr;7(2):95-104
references.pmid: 9559495
references.citation: Arch Ophthalmol. 2006 Jan;124(1):12-9
references.pmid: 16401779
references.citation: Natl Vital Stat Rep. 2006 Apr 19;54(14):1-40
references.pmid: 16681183
references.citation: J Glaucoma. 2002 Apr;11(2):154-63
references.pmid: 11912364
references.citation: Arch Ophthalmol. 1997 Nov;115(11):1447-55
references.pmid: 9366678
references.citation: Int J Technol Assess Health Care. 2000 Autumn;16(4):1158-67
references.pmid: 11155835
references.citation: Br J Ophthalmol. 2001 Mar;85(3):327-31
references.pmid: 11222340
references.citation: Invest Ophthalmol Vis Sci. 1992 Jun;33(7):2224-8
references.pmid: 1607232
references.citation: Pharmacoeconomics. 1998 Apr;13(4):397-409
references.pmid: 10178664
references.citation: Br J Ophthalmol. 2003 Oct;87(10):1201-4
references.pmid: 14507746
references.citation: Vital Health Stat 2. 2000;(129):1-28
references.pmid: 11824050
references.citation: Arch Ophthalmol. 2003 Jan;121(1):108-12
references.pmid: 12523894
references.citation: Osteoporos Int. 2001;12(5):356-61
references.pmid: 11444082
references.citation: Arch Ophthalmol. 2004 Apr;122(4):532-8
references.pmid: 15078671
references.citation: Arch Intern Med. 2003 Jul 28;163(14):1637-41
references.pmid: 12885677
references.citation: N Engl J Med. 2004 May 20;350(21):2199-203
references.pmid: 15152067
references.citation: Am J Ophthalmol. 2006 Jun;141(6):997-1008
references.pmid: 16765666
references.citation: Arch Ophthalmol. 2002 Jun;120(6):701-13; discussion 829-30
references.pmid: 12049574
references.citation: Ophthalmology. 1998 Nov;105(11):2099-104
references.pmid: 9818612